このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

眠気の客観的評価のための脳波解析 (MEEGASAFE)

2026年9月16日 更新者:Physip S.A

偶発的なリスクを制限するための二次性過眠症の客観的評価のためのEEG分析

The objective of this clinical study is to develop solutions for the evaluation and management of drowsiness, based on 2 EEG sensors only, aiming at reducing the risk of accidents related to secondary hypersomnolence (sleepiness induced by sleep restriction or abnormal sleep/wake cycle). This project will allow a better understanding of the determinants of drowsiness and its impact on cognitive performance and the development of methods and models for the evaluation and prediction of cognitive performance deficit related to sleepiness. The secondary hypersomnolence will be objectified by continuous EEG recording and analysed by visual reading according to Objective Sleepiness Scale (OSS) criteria and automatically analyzed using the MEEGAWAKE algorithm (developed by PHYSIP). The level of secondary hypersomnolence will be modified by varying the duration and maintening of prior sleep or the sleep timing. The ability to stay awake will be measured by the maintenance of wakefulness test (MWT). Subjective sleepiness and mind wandering will be measured before and/or after all measurements. Simulated driving task, maintenance of wakefulness tests and several cognitive tasks to measure sustained attention, alertness, selective attention will be performed every 4 hours.

調査の概要

状態

積極的、募集していない

条件

詳細な説明

Chronotype and general tendency to daydream in daily life will be evaluated at the inclusion visit. Healthy volunteers will be placed in sleep deprivation patterns that will modify the level of secondary hypersomnolence. These patterns correspond to sleep deprivation caused by work schedules usually observed: shift work (SDP1) or night on-call (SDP2). shift work will be simulated by total sleep deprivation for 24 hours (comparable to the first day of a night worker) followed by early morning sleep, and an extended 17 hours wakefulness (comparable to second day of night shift). Secondary hypersomnolence will be assessed throughout prolonged awakenings (24 hours + 17 hours). The night on-call will be simulated by two half-hour awakenings during the nocturnal sleep. Hypersomnolence will be measured within 17 hours of wakefulness following this sleep fragmentation. The sleep history (quantity and quality of sleep) will be evaluated by actigraphy + ambulatory polysomnography (1 day before the experiment) and 2 polysomnographies in the laboratory during the experiment. Polysomnography recordings will be visually and automatically analyzed by the ASEEGA algorithm. Ambulatory recordings are automatically analyzed by ASEEGA. Throughout these sleep deprivation patterns, electrophysiological variables (EEG, EOG and EMG) will be continuously recorded in order to identify objective drowsiness states determined visually using the OSS or automatically by the MEEGAWAKE algorithm. Subjective sleepiness scale, Mind wandering scale, maintenance of wakefulness tests (MWT, electrophysiological test) and cognitive tests will be repeated, every 4hr, throughout the sleep deprivation patterns in order to determine abilities to stay awake, driving performance, sustained and selective attention, vigilance.

研究の種類

介入

入学 (実際)

40

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

20年~60年 (大人)

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

説明

Inclusion Criteria:

  • BMI between 18 and 27,
  • With a score on the PHQ-4 scale less than or equal to 2 for scores A (Anxiety) and D (Depression),
  • Subjects with no complaints of excessive daytime sleepiness (total ESS score <11),
  • Non-professional drivers,
  • Subjects who have held their driving license for at least one year,
  • Subjects affiliated to a social security scheme,
  • Subjects able to understand the study,
  • Subjects available to come to the 3 visits required by the study,
  • Free, informed and written consent signed

Exclusion Criteria:

  • Pathologies that can induce excessive daytime sleepiness: untreated narcolepsy or idiopathic hypersomnia, untreated restless legs syndrome, untreated periodic leg movement syndrome,
  • Chronic insomnia disorder,
  • Excessive alcohol consumption (> 2 glasses per day) during the last 6 months,
  • Excessive consumption of coffee, tea or cola-type caffeinated beverages (> 5 cups/day),
  • Severe pathologies involving the vital prognosis in the short term,
  • Uncontrolled endocrine pathologies (dysthyroidism, diabetes),
  • All progressive cardiac pathologies, treated or untreated,
  • All progressive neurological conditions treated or not (brain tumor, epilepsy, migraine, stroke, sclerosis, myoclonus, chorea, neuropathy, muscular dystrophies, myotonic dystrophy, etc.),
  • Substance dependence,
  • Shift workers or night workers who have performed on-call or on-call duty in the last 72 hours,
  • Patients taking psychotropic drugs (antidepressants, antihistamines),
  • Long-term treatment with benzodiazepines and z-drugs,
  • Patients on cardiotropic,
  • Deprived of liberty by a judicial or administrative decision,
  • Pregnant or breastfeeding woman,
  • Subject under legal protection (guardianship, wardship) or deprived from his rights following administrative or judicial decision

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:基礎科学
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Sleep deprivation

healthy volunteers

Sleep deprivation patterns 1 (SDP1) ; total sleep deprivation for 24 hours followed by early morning sleep and an extended 17 hours wakefulness. Sleep deprivation patterns 2 (SDP2) : Sleep interrupted by two half-hour awakenings

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change in Objective Sleepiness Scale (OSS) during extended wakefulness
時間枠:Once every 4 hours during SDP1 and SDP2 wakefulness

OSS is based on the visual analysis of electrophysiological variables (EEG (C4, O2, C3, P3), 1 vertical EOG and 1 horizontal EOG).

Each state of drowsiness (score) corresponds to a specific EEG activity accompanied by well-differentiated blinking and eye movements

Once every 4 hours during SDP1 and SDP2 wakefulness

二次結果の測定

結果測定
メジャーの説明
時間枠
Change in Karolinska sleepiness scale (KSS) during extended wakefulness
時間枠:12 assessments every 4 hours during SDP1 and SDP2 wakefulness

The KSS is a self-administered questionnaire that measures, on a 10 point Likert scale ranging from=1 to "fully awake" to 10 ="extremely drowsy". This measure has very good external validity on EEG synchronization measures and on the cognitive and behavioral performance of subject in relation to his or her ability to maintain wakefulness.

12 assessments every 4 hours during SDP1 and SDP2 wakefulness
Change in sleep onset mesured by Maintenance of Wakefulness Test (MWT) during extended wakefulness
時間枠:Once every 4 hours during SDP1 and SDP2 wakefulness

This is test ability to stay awake in laboratory conditions conductive to falling asleep. The sleep onset latency is obtained during an electrophysiological test (EEG, EMG and EOG).

Once every 4 hours during SDP1 and SDP2 wakefulness
Change in number of inappropriate line crossings (driving performance) during extended wakefulness
時間枠:Once every 4 hours during SDP1 and SDP2 wakefulness

On the driving simulator the subjects will drive on a highway scenario representing a reconstruction of the real highway. Number of inappropriate line crossings (ILC) will mesured.

An ILC was recorded when the car crossed a right or left lateral lane marker, whatever the duration and the amplitude of the crossing. Exceptions were overtaking manoeuvres or some other necessary driving action.

Once every 4 hours during SDP1 and SDP2 wakefulness
Change in Standard deviation of the lateral position of the car (driving performance) during extended wakefulness
時間枠:Once every 4 hours during SDP1 and SDP2 wakefulness

On the driving simulator the subjects will drive on a highway scenario representing a reconstruction of the real highway. Standard deviation of the lateral position of the car (SDLP in cm) will mesured.

Lateral Position was defined as being 0 when the car was in the center of the lane, with positive value to the right and negative values to the left.

Once every 4 hours during SDP1 and SDP2 wakefulness
Change Sustained and selective attention during extended wakefulness
時間枠:Once every 4 hours during SDP1 and SDP2 wakefulness

The reaction time of subject to the presentation of a "target" stimulus (Continuous Performance Test, CPT)

Once every 4 hours during SDP1 and SDP2 wakefulness
Change in Vigilance during extended wakefulness
時間枠:Once every 4 hours during SDP1 and SDP2 wakefulness

The test examines the ability to concentrate and maintain attention over a long period (30mn) (TAP vigilance test)

Once every 4 hours during SDP1 and SDP2 wakefulness
Change in Simple reaction time test (PVT) during extended wakefulness
時間枠:1 time every 4 hours during SDP1 and SDP2 wakefulness

Reaction-timed task that measures the consistency with which subjects respond to a visual stimulus.

1 time every 4 hours during SDP1 and SDP2 wakefulness
Change in conscious experience during extended wakefulness
時間枠:5 assessments every 4 hours during SDP1 and SDP2 wakefulness

Questionnaire suggests participant's attention and thoughts were entirely focused on task-related stimuli

5 assessments every 4 hours during SDP1 and SDP2 wakefulness
Munich Chorotype Questionnaire
時間枠:Once time during inclusion. Visit V0

The Munich Chorotype Questionnaire (MCTQ) quantifies the chronotype according to the phase of entrainment based on the reported the mid-time of sleep; The MCTQ parameters are mid-sleep on weekdays (MSW in hr), mid-sleep on free days (MSF in hr) and mid-sleep on free days corrected for sleep debt on weekdays (MSFsc in hr). The MSFsc score (used as a chronotype indicator) represents a continuum of circadian preference, with an increasing tendency toward the evening type. MCTQ parameters are represented by hours, ranging from 0 hour (extreme morningness) to 12 hours (extreme eveningness).

Once time during inclusion. Visit V0
Horne and Ostberg morning/evening questionnaire (MEQ)
時間枠:Once time during inclusion. Visit V0

The Horne and Ostberg morning/evening questionnaire (MEQ) quantifies the chronotype.

The MEQ contains19 questions on life preferences (activity, sleep-wake cycle, meals) and the state of fatigue and drowsiness at certain times of the day. The MEQ score ranges from 16-86, with evening type ranging from16-41, neither or intermediate type from 42-58, and morning type from 59-86.

Once time during inclusion. Visit V0
Daydreaming frequency scale
時間枠:Once time during inclusion. Visit V0

To assess participants' general tendency to daydream in daily life

Once time during inclusion. Visit V0
Total sleep time (PSG)
時間枠:2 times before SDP1 and SDP2

Total sleep time, the number of minutes asleep in bed after "lights off", will be calculated using a polysomnographic recording (PSG). EEG, EOG and EMG will be recorded during sleep.

2 times before SDP1 and SDP2
Sleep onset latency (PSG)
時間枠:2 times before SDP1 and SDP2

Sleep onset latency, the minutes from lights off to sleep onset, will be calculated using a polysomnographic recording (PSG). EEG, EOG and EMG will be recorded during sleep.

2 times before SDP1 and SDP2
Sleep efficiency (PSG)
時間枠:2 times before SDP1 and SDP2

Sleep efficiency, the ratio of the total time spent asleep (total sleep time) in a night compared to the total amount of time spent in bed, will be calculated using a polysomnographic recording (PSG). EEG, EOG and EMG will be recorded during sleep.

2 times before SDP1 and SDP2
Amount of sleep stages (PSG)
時間枠:2 times before SDP1 and SDP2

Amount of N1,N2,N3 and R stage (expressed in p% of TST) will be calculated using a polysomnographic recording (PSG). EEG, EOG and EMG will be recorded during sleep.

2 times before SDP1 and SDP2
Wake after sleep onset (PSG)
時間枠:2 times before SDP1 and SDP2

Wake after sleep onset, number of minutes scored as wake from sleep onset to the last minute scored as sleep while in bed, will be calculated using a polysomnographic recording (PSG). EEG, EOG and EMG will be recorded during sleep.

2 times before SDP1 and SDP2
Total sleep time (actigraphy)
時間枠:2 times before SDP1 and SDP2

Total sleep time, the number of minutes asleep in bed after "lights off", will be calculated using an actigraph (wearable sleep test that tracks wrist movements)

2 times before SDP1 and SDP2
Sleep onset latency (actigraphy)
時間枠:2 times before SDP1 and SDP2

Sleep onset latency, the minutes from lights off to sleep onset, will be calculated using an actigraph (wearable sleep test that tracks wrist movements)

2 times before SDP1 and SDP2
Sleep efficiency (actigraphy)
時間枠:2 times before SDP1 and SDP2

Sleep efficiency, the ratio of the total time spent asleep (total sleep time) in a night compared to the total amount of time spent in bed will be calculated using an actigraph (wearable sleep test that tracks wrist movements)

2 times before SDP1 and SDP2
Wake after sleep onset (actigraphy)
時間枠:2 times before SDP1 and SDP2

Wake after sleep onset, number of minutes scored as wake from sleep onset to the last minute scored as sleep while in bed will be calculated using an actigraph (wearable sleep test that tracks wrist movements)

2 times before SDP1 and SDP2

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Jean-Arthur Micoulaud-Franchi, MD/PhD、University Hospital, Bordeaux

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2023年3月8日

一次修了 (実際)

2025年5月23日

研究の完了 (推定)

2027年6月30日

試験登録日

最初に提出

2022年6月14日

QC基準を満たした最初の提出物

2022年7月6日

最初の投稿 (実際)

2022年7月12日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月21日

QC基準を満たした最後の更新が送信されました

2026年9月16日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する